Trevena INC 8-K filings

Trevena, Inc. has settled its royalty-based loan agreement with R-Bridge Investment Four Pte. Ltd. by assigning its China royalty rights for Olinvyk, while retaining commercialization milestone payments.

Trevena, Inc. enters into a securities exchange agreement to exchange outstanding warrants for cash, common stock, and a new pre-funded warrant.

Trevena, Inc. implements cost-cutting measures including a director's resignation, an officer's termination, and a subsequent consulting agreement with the terminated officer.

Trevena, Inc. has ceased the sale of its remaining OLINVYK dosage strengths, citing business and financial considerations.

Trevena Inc. has appointed Katrine Sutton as its new principal financial officer and principal accounting officer, effective November 26, 2024, replacing Barry Shin.

Trevena reported a net loss of $4.9 million for Q3 2024, alongside significant cost-cutting measures including executive departures and a board reduction.

Trevena, Inc. has terminated the employment of its CEO, COO/CFO, and CMO as part of cost-cutting measures, while simultaneously entering into consulting agreements with the latter two.

Trevena Inc. will be delisted from the Nasdaq Stock Market due to failure to meet minimum stockholders' equity requirements, with trading expected to move to the Pink Open Market.

Trevena Inc. has regained compliance with Nasdaq's minimum bid price rule but has been granted an extension until October 2, 2024, to meet the minimum stockholders' equity requirement.

Trevena, Inc. has implemented a 1-for-25 reverse stock split of its common stock, effective August 13, 2024, to meet Nasdaq's minimum bid price requirement.

Trevena reported its second quarter 2024 financial results, highlighted positive preclinical data for TRV045, and completed a $12 million financing.

Trevena, Inc. announced a $2 million non-dilutive financing tranche and a $10 million reduction in outstanding liabilities through an amendment to its existing ex-US royalty financing agreement.

Trevena Inc. held its annual meeting on June 13, 2024, where shareholders voted on several key proposals, including the election of directors, ratification of the accounting firm, and approval of a reverse stock split.

Trevena announced its first quarter 2024 financial results, provided an update on its clinical programs, and received an extension from Nasdaq to regain compliance with listing requirements.

Trevena Inc. successfully obtained shareholder approval for a share issuance related to warrants at a special meeting held on April 19, 2024.

Trevena Inc. has received a notice from Nasdaq stating it no longer meets the minimum stockholders' equity requirement for continued listing, adding to existing concerns about its share price.

Trevena is reducing commercial support for OLINVYK and focusing resources on the development of TRV045, a novel S1P receptor modulator, after reporting a net loss of $16.5 million for the fourth quarter of 2023.

Trevena Inc.'s Special Meeting of Stockholders was adjourned due to a lack of quorum and will reconvene on April 19, 2024.

Trevena, Inc. is facing potential delisting from the Nasdaq Capital Market after failing to maintain a minimum share price of $1.00, and has requested a hearing to appeal the decision.

Trevena Inc. has promoted Barry Shin to Executive Vice President, Chief Operating Officer & Chief Financial Officer, effective February 1, 2024.